Cytogel Pharma, LLC

? At Cytogel Pharma, LLC we recognize the critical role education plays in transforming the landscape of pain management. Inspired by the Institute of Medicine's call for a cultural shift, this initiative would not only increase public and patient understanding of pain but also involve an array of public and private partners, utilizing diverse outreach?strategies to?reach?different population segments effectively. ? Such campaigns are essential for addressing the pervasive stigmatization and misconceptions around pain, which are significant barriers to effective treatment. By collaborating with federal agencies, healthcare providers, and various advocacy groups, we can foster a community well-informed about the complexities of?pain and the importance of safer medication practices.? ? Join us as we support efforts to make?pain better understood. Our aim is to develop analgesics which provide “opioid-like efficacy and non-opioid-like safety”. #PainAwareness?#SaferPainTreatment?

? Exciting Highlights from the 2024 MedInvest Biotech and Pharma Investor?Conference: We’re proud to share that our Chief Scientific Officer, Dr.?Ted Maione??presented at the??2024 MedInvest Biotech and Pharma Investor?Conference??in New York. In collaboration with the The National Institutes of Health and O'Melveny & Myers LLP, the event gathered leading voices in life sciences and healthcare to discuss the latest trends and opportunities in biotech investment. ?? Dr. Maione, joined by our CEO,?C. Dean Maglaris, showcased Cytogel Pharma, LLC's innovative research and development efforts, particularly our promising CYT-1010 program, which is advancing into Phase 2 clinical development after successful Phase 1 results. His extensive experience in the biotech industry and dedication to identifying breakthrough solutions for pain management is driving our mission forward. ?? Dean?Maglaris led individual meetings and emphasized the importance of our work at Cytogel, highlighting our commitment to developing effective therapies that address real patient needs. With extensive experience in the pharmaceutical sector, his leadership continues to guide Cytogel’s vision for transformative drug development. ?? We are proud to be part of this vibrant community and look forward to the collaborative opportunities ahead. Together, we are paving the way for innovative solutions in healthcare. ?#Biotech #PharmaInnovation #HealthcareLeadership ?? https://lnkd.in/gwFv_F-H MedInvest Conferences, Perkins Coie, Goodwin, Cooley LLP, O'Melveny & Myers LLP, Torrey, Marcum LLP, Wilson Sonsini Goodrich & Rosati

Honored that #profilesinmentalhealthcourage made the list of Penguin Random House’s “Books for Emotional Wellness Month”! https://lnkd.in/eYq432Cw Stephen Fried

We commend initiatives like El Paso Community College's recent launch of a free NARCAN distribution campaign. As they make strides in providing access to lifesaving treatments on their campuses, it underscores the critical need for continued research for non-addictive pain management solutions. At Cytogel Pharma, LLC we are dedicated to contributing to this effort by advancing CYT-1010, our?endomorphin-based?compound, a promising effective??analgesic with an improved profile of safety over traditional opioids,?namely minimized risk of addiction and the avoidance of respiratory depression. Our aim is not just to innovate, but to be part of a larger movement that supports community health and prevents the devastating impact of opioid overdoses. Let's continue to push forward, innovate, educate and create safer communities together. ?#HealthcareInnovation #PainManagement #CommunityHealth https://lnkd.in/gVB6gwHR

Kelowna Capital News and Brittany Webster’s article highlights?the proactive steps taken by Kelowna-based Custom Health Inc., as they play a crucial role in the launch of the new Opioid Addiction Deterrence Task Force in Washington, D.C. This task force, spearheaded by the American Medical Technology Coalition (AMTC), is a testament to the power of collaboration across borders and industries in the fight against the opioid epidemic. ? Shane Bishop, CEO of Custom Health and Executive Director of AMTC, emphasized the task force's commitment to integrating advanced technology, data analytics, and comprehensive community engagement to revolutionize pain management and reduce opioid misuse. ? At Cytogel Pharma, LLC we are moved by such collaborative efforts and remain committed to our mission of developing safer, non-addictive pain management alternatives. Through our ongoing clinical development of CYT-1010, we are implementing a focused program around pain management, to culminate with the dual advantage of “opioid-like efficacy and non-opioid-like safety” namely minimized risk of addiction and the avoidance of respiratory depression. #SaferPainTreatment https://lnkd.in/gK7wVDRv

In a compelling article by Carrie MacMillan, Dr. David Fiellin of Yale Program in Addiction Medicine explores the disturbing rise of fentanyl as a major driver of opioid overdose deaths. Fentanyl's potency (50-100 times stronger than many prescription opioids) and synthetic nature make it both accessible and deadly. ? The shift from medical use to illicit manufacturing has exacerbated its danger. Drug dealers often mix fentanyl with other substances even counterfeit prescription pills, making it nearly impossible for users to know what they're taking.? ? In 2022, fentanyl was a leading cause in nearly 83,000 opioid-related deaths in the U.S., according to the CDC. This crisis calls for urgent actions to address and mitigate the impact of this lethal drug. ? At Cytogel Pharma, LLC we are working tirelessly?on developing CYT-1010, a?potentially?safer, non-addictive pain treatment?aimed at providing relief without the risks associated with current opioid?analgesics. ? #OpioidCrisis #PainManagement #HealthcareInnovation

A recent article from Spectrum News highlights the?3rd?Annual?Hawaii?Fentanyl and Addiction Summit, an initiative taking on the opioid crisis that continues to impact communities across Hawaii. Since its inception in 2022, the Summit has become a pivotal platform for stakeholders from diverse backgrounds—community leaders, healthcare professionals, and task force members—to come together and combat this urgent?public?health challenge. ? The County of Hawaii’s?Mayor, Mitchell Roth, emphasized: "We are committed to doing all we can to protect our community from the opioid and fentanyl epidemic.” ? Dr. Hannah Preston-Pita, CEO of the Big Island Substance Abuse Council, highlighted the proximity of the crisis: "This epidemic is much closer to your household than you might think.” ? At Cytogel Pharma, LLC this mission resonates deeply with us. As we develop our innovative compound, CYT-1010, we are dedicated to providing?an alternative that would be a?safer, non-addictive pain treatment. Our work is aligned with the goals of saving lives by offering safer alternatives and raising awareness in pain treatments.? ? Together, we can make a significant difference in the fight against this devastating epidemic. ? #PublicHealth #PainManagement #HealthcareInnovation https://lnkd.in/gbcDkU6A

We at Cytogel Pharma, LLC extend our heartfelt thanks to LinkedIn for inviting us to participate in a recent survey. As we advance the development of our CYT-1010 compound, aimed at revolutionizing pain management, opportunities like this play a helpful role in expanding our engagement with the medical, scientific, and investment communities, as well as industry leaders. We are delighted to have shared our experiences and insights. Even more commendable was LinkedIn's generous gesture of making a donation to Doctors Without Borders/Médecins Sans Frontières - USA on our behalf as a token of appreciation for our participation. This act of kindness not only supports a noble cause, it also enriches our commitment to making a positive impact on global health. Thank you, LinkedIn, for this wonderful initiative and for amplifying our mission to provide safer pain treatment options. #LinkedIn?#SocialImpact #InnovationInHealthcare https://lnkd.in/dR9CdGm

A recent Bloomberg Businessweek article by Gerry Smith offers a deep dive into the complexities of the pharmaceutical landscape that we at Cytogel Pharma, LLC navigate daily. This insightful piece sheds light on the search for opioid alternatives which, for the most part, have fallen short because of the lack of superior efficacy. He quotes:?“Opioids are the most effective fast-acting meds that we have,” says Gerard Limerick, an assistant professor at Johns Hopkins Medicine. Most, if not all, drugs in development have failed to achieve that level of efficacy and, without that aspect, will face limited utilization. With this in mind, a more focused goal in this arena would be to develop a drug that provides both opioid-like efficacy and non-opioid-like safety.?That is our goal at Cytogel Pharma and we are making strides toward that end. ? Discussions such as this by Mr. Smith are not only enlightening but also affirm our commitment to pioneering solutions in pain management. The challenges highlighted reinforce the importance of our mission to innovate responsibly and effectively. ? Join us as we continue to push the boundaries of what's possible in medical science for better, safer patient outcomes. ? #CytogelPharma #PainManagement #HealthcareInnovation #PharmaChallenges #Opportunity

With the addition of Michael Ullmann, alongside notable figures including Jerry Leamon,?Chris Christie,?Patrick J. Kennedy, and Gale S. Pollock, our Board and Advisory Council reflect a spectrum of expertise across healthcare, law, and public policy. This diverse leadership is helping steer the continued development of CYT-1010, our pioneering pain treatment which we anticipate will be safe with no risk of addiction. Stay tuned as we redefine pain management together! ? ???Learn more about our team?https://lnkd.in/gwGC7s8e #TeamCytogel?#HealthcareInnovation #SaferPainTreatments